• Treatment failure (death within 30 days of inclusion, or later if judged as related to Human African trypanosomiasis; termination of treatment due to adverse events; evidence of infection relapse at or after discharge, up to 24 months post discharge) [ Time Frame: 24 months ]
  

• Occurrence and severity of serious clinically apparent adverse events [ Time Frame: treatment period and up to one month post discharge ]
  
• Occurrence and severity of biochemical (ALAT, creatinine, bilirubin) and haematological (abnormal total and differential leukocyte count, haemoglobin) adverse events [ Time Frame: treatment period ]
  

Inclusion Criteria:

• Stage 2 infection with Trypanosoma brucei gambiense diagnosed within the previous 14 days, as defined by either of the following: (i) Presence of trypanosomes in blood or lymph node fluid and WBC count in CSF > 5 / mm3, or (ii) Presence of trypanosomes in the CSF with any CSF WBC count
• Residence in the study area
• Written informed consent (to be obtained from parent/guardian for children under 18 years and patients with impaired cognition)

Exclusion Criteria:

• Pregnancy or clinical history suggestive thereof
• Weight < 10 Kg
• History of any HAT treatment within the previous 24 months
• Inability to undergo hospitalisation or attend follow-up visits during the 24 months following discharge
• Severe anemia (Hb< 5g/dl)
• Active tuberculosis (sputum positive)
• HIV positive (if patient has been tested and results are known)
• Severe renal or hepatic failure
• Bacterial or cryptococcal meningitis
• Other severe underlying diseases upon admission
• Refugee status